Research programme: colorectal cancer therapies - Abraxis BioScience/University of Southern California
Latest Information Update: 16 Jul 2016
At a glance
- Originator University of Southern California
- Developer Celgene Corporation; University of Southern California
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Colorectal cancer